Fig. 11From: Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activityRepresentative immunostainings of dCK. The immunohistochemistry panel shows representative figures of negative/weak, intermediate, and strong dCK staining assessed by digital scoring using HALO™Back to article page